Additional file 2 of A composite biomarker of neutrophil-lymphocyte ratio and hemoglobin level correlates with clinical response to PD-1 and PD-L1 inhibitors in advanced non-small cell lung cancers

Additional file 2: Supplementary Fig. 2. Association of red blood cell counts (A and B), or hematocrit (C and D) with OS at baseline or 2–8 weeks after initiation of treatment.